BRPI1016182A2 - método para o tratamento da leucemia mieloide aguda - Google Patents

método para o tratamento da leucemia mieloide aguda

Info

Publication number
BRPI1016182A2
BRPI1016182A2 BRPI1016182A BRPI1016182A BRPI1016182A2 BR PI1016182 A2 BRPI1016182 A2 BR PI1016182A2 BR PI1016182 A BRPI1016182 A BR PI1016182A BR PI1016182 A BRPI1016182 A BR PI1016182A BR PI1016182 A2 BRPI1016182 A2 BR PI1016182A2
Authority
BR
Brazil
Prior art keywords
treatment
myeloid leukemia
acute myeloid
acute
leukemia
Prior art date
Application number
BRPI1016182A
Other languages
English (en)
Inventor
Löwenberg Bob
Lavrencic Mojca
Jacobus Maria Vlak Peter
Ming Sun Su
Original Assignee
Univ Erasmus Med Ct Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus Med Ct Rotterdam filed Critical Univ Erasmus Med Ct Rotterdam
Publication of BRPI1016182A2 publication Critical patent/BRPI1016182A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI1016182A 2009-04-22 2010-04-22 método para o tratamento da leucemia mieloide aguda BRPI1016182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09158496A EP2243833A1 (en) 2009-04-22 2009-04-22 Method for the treatment of acute myeloid leukemia
PCT/EP2010/055355 WO2010122109A1 (en) 2009-04-22 2010-04-22 Method for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
BRPI1016182A2 true BRPI1016182A2 (pt) 2019-09-24

Family

ID=40935648

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1016182A BRPI1016182A2 (pt) 2009-04-22 2010-04-22 método para o tratamento da leucemia mieloide aguda

Country Status (10)

Country Link
US (1) US20120088811A1 (pt)
EP (2) EP2243833A1 (pt)
JP (1) JP2012524758A (pt)
KR (1) KR20110138414A (pt)
CN (1) CN102421899A (pt)
BR (1) BRPI1016182A2 (pt)
CA (1) CA2759597A1 (pt)
EA (1) EA201101531A1 (pt)
MX (1) MX2011010610A (pt)
WO (1) WO2010122109A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515024A (ja) * 2011-04-12 2014-06-26 ベス イスラエル デアコネス メディカル センター， インコーポレイテッド マイクロｒｎａ阻害剤および疾患におけるその使用
JP6156621B2 (ja) * 2012-02-14 2017-07-05 国立大学法人 岡山大学 Ａｔｌｌの診断のためのデータ取得方法、ａｔｌｌ診断用キットおよびａｔｌｌ診断システム
EP3036345A2 (en) * 2013-08-19 2016-06-29 Notre Dame Du Lac Method and composition for detection of oncogenic hpv
US9822358B2 (en) 2013-10-18 2017-11-21 Beth Israel Deaconess Medical Center Treatment of cancers with micro-RNA inhibitors
KR101476781B1 (ko) * 2014-05-09 2014-12-29 충남대학교산학협력단 결핵 진단용 바이오마커 마이크로 rna
KR20210089270A (ko) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
CN106367474B (zh) * 2015-07-21 2020-01-31 益善生物技术股份有限公司 18种miRNA检测探针和液相芯片
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
CN114392346A (zh) * 2022-01-19 2022-04-26 山东大学齐鲁医院 亨廷顿相互作用蛋白-1相关蛋白基因和/或其编码的蛋白的新应用

Also Published As

Publication number Publication date
JP2012524758A (ja) 2012-10-18
EP2421968A1 (en) 2012-02-29
CN102421899A (zh) 2012-04-18
WO2010122109A1 (en) 2010-10-28
MX2011010610A (es) 2012-01-30
EP2243833A1 (en) 2010-10-27
US20120088811A1 (en) 2012-04-12
CA2759597A1 (en) 2010-10-28
EA201101531A1 (ru) 2012-05-30
KR20110138414A (ko) 2011-12-27
WO2010122109A9 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
LTPA2018001I1 (lt) Suderinta terapija, skirta LOPL
BRPI0921482A2 (pt) tratamento de leucemia linfoblástica aguda
BRPI1016182A2 (pt) método para o tratamento da leucemia mieloide aguda
HK1166331A1 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases -tau ps422
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI0921341A2 (pt) tratamento de leucemia linfoblástica aguda pediátrica
CO6821964A2 (es) Compuestos para el tratamiento de la adicción
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0922871A2 (pt) metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
BRPI1012237A2 (pt) método para produção de hidrocarbonetos aromáticos
BRPI0922490A2 (pt) Método para produção de beta-santaleno
BRPI1007459A2 (pt) método para produção de manômeros olefínicos
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1007391A2 (pt) processo para o resfriamento controlado da troposfera
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
DE112009002122A5 (de) Beschichtungsverfahren
BR112012009360A2 (pt) processo para estabilização de hipofosfito.
DK2346661T3 (da) Dannelsesfremgangsmåder
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI1008016A2 (pt) método para o tratamento de águas residuais
BRPI0813832A2 (pt) Métodos para tratamento da ansiedade
BRPI1013792A2 (pt) processo para biorefinaria.
BR112012003653A2 (pt) "método de tratar o câncer."
BR112012002267A2 (pt) compostos para o tratamento de inflamação.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.